Actively Recruiting
Phase 1 Study to Evaluate Safety and Pharmacokinetics of a Single 30 mg Oral Dose of Quizartinib in Adults With Severe Liver Impairment Compared to Healthy Adults
Led by Daiichi Sankyo · Updated on 2026-04-01
12
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the pharmacokinetics how the body absorbs, distributes, metabolizes, and eliminates a drug of quizartinib in people with severe hepatic impairment compared to healthy individuals with normal liver function. This Phase 1 clinical pharmacology study aims to assess the safety and tolerability of quizartinib in these two groups using established liver function criteria called Child-Pugh. The study is sponsored by Daiichi Sankyo and conducted at up to three sites in the US. Participants will receive a single oral dose of 30 mg quizartinib. There are two groups one with severe hepatic impairment and a matched healthy control group. Both groups will receive the same single dose to compare how the drug behaves in the body between those with liver impairment and healthy subjects. The study design is open-label and non-randomized. During the study, participants will be monitored from the first dose through 29 days to measure pharmacokinetic parameters such as maximum concentration Cmax, time to maximum concentration Tmax, area under the curve AUClast and AUCinf, and half-life t12. Safety will be assessed by recording any adverse events up to 30 days after the last measurement. The total participation duration includes the dosing day and follow-up visits for up to about one month.
CONDITIONS
Brief Title
Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment
Research Team
D
Daiichi Sankyo Contact for Clinical Trial Information
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here